Clinical Trials Arena on MSN5d
Helicore doses first subject in Phase I trial of obesity treatmentUS-based biopharmaceutical company Helicore Biopharma has dosed the first subject in a randomised, first-in-human Phase I ...
Hosted on MSN3mon
Proteomics method identifies ligand-binding proteins and binding sites in complex systemsMonitoring protein-ligand interactions is thus essential for characterizing proteins with unknown functions, for investigating regulatory mechanisms in cell metabolism, and for elucidating drug ...
JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences ...
Ligand Pharmaceuticals Inc (NASDAQ:LGND) reported a 28% increase in royalty revenue and a 40% increase in core adjusted EPS for 2024. The company has a strong financial position with over $250 ...
(RTTNews) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal 2025 forecast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback